The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database
Abstract
OBJECTIVE: To provide population-based estimates of the prevalence of lipodystrophy syndrome and constituent symptoms and to identify correlates of prevalent symptomology. METHODS: Participants in a province-wide HIV/AIDS treatment programme reported morphological and metabolic abnormalities. Probable lipodystrophy was defined as self-report of at least one morphological abnormality or both high cholesterol and triglyceride levels. Explanatory variables investigated included: age; sex; ethnicity; transmission risk group; CD4 cell count; plasma viral load; AIDS diagnosis; duration of infection; alternative therapy use; past, current and duration of use of antiretroviral therapy (ART) by class and specific drug; total duration of ART; and current adherence. Stepwise logistic regression identified possible determinates of lipodystrophy. RESULTS: Of 1035 participants, 50% appeared to have probable lipodystrophy, with 36% reporting peripheral wasting, 33% abdominal weight gain, 6% buffalo hump, and 10 and 12% increased triglyceride or cholesterol levels, respectively. In multivariate analysis, lipodystrophy was associated with older age (per year) (AOR 1.03; 95% CI 1.01, 1.04), the use of ingested alternative therapies (AOR 1.46; 95% CI 1.06, 2.01), having ever used protease inhibitors (PI) (AOR 2.63; 95% CI 1.89, 3.66), and duration of stavudine treatment (per year) (AOR 1.35; 95% CI 1.15, 1.58). In analysis limited to participants exposed to PI, after similar adjustment, the duration of lamivudine rather than stavudine treatment was associated with lipodystrophy (AOR 1.32; 95% CI 1.13, 1.53). CONCLUSION: Increased risk of abnormalities is associated with the use of PI, and the duration of stavudine and lamivudine treatment after adjustment for personal characteristics, clinical disease stage, duration of infection and detailed treatment history.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065 · cited 2×
“Others have reported similar [41,42] or higher [4,43] rates of prevalent morphological changes, whereas most clinical studies [4,24,43] Table 4.”
ResultWalli, R., Herfort, O., Michl, G. M., Demant, T., Jäger, H., Dieterle, C., Bogner, J. R., Landgraf, R., & Goebel, F. D. (1998) · AIDS · doi:10.1097/00002030-199815000-00001 · Cited by 519
Cited by
Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., & Louis, T. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022048 · Cited by 625
Wood, E., Hogg, R. S., Yip, B., Harrigan, P. R., O'Shaughnessy, M. V., & Montaner, J. S. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00008 · Cited by 359
Self-citationDuran, S., Savès, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., Salmon, D., Moatti, J.-P., & Leport, C. (2001) · AIDS · doi:10.1097/00002030-200112070-00012 · Cited by 284
van Leth, F., Phanuphak, P., Stroes, E., Gazzard, B., Cahn, P., Raffi, F., Wood, R., Bloch, M., Katlama, C., Kastelein, J. J. P., et al. (2004) · PLoS Medicine · doi:10.1371/journal.pmed.0010019 · Cited by 276
HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management
Carr, A. (2003) · AIDS · doi:10.1097/00002030-200304001-00017 · Cited by 275
Metadata
- Authors
- Heath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaughnessy, M. V., & Montaner, J. S. G.
- Venue
- AIDS
- Published
- 2001-01
- Volume
- 15
- Issue
- 2
- Pages
- 231-239
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2075669690
- Cited by
- 249
- References
- 2
- FWCI
- 41.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. https://app.cochat.ai/papers/10.1097/00002030-200101260-00013
- The paper
- Heath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaughnessy, M. V., & Montaner, J. S. G. (2001). Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. https://doi.org/10.1097/00002030-200101260-00013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.